Daily Archives: April 5, 2017

Human Genetics Market Analysis and Global Forecast to 2024 … – Digital Journal

Posted: April 5, 2017 at 4:23 pm

"Human Genetics Market Research Report - Global Forecast to 2024"

Human genetic market, by instruments (Accessories, Device), by end-user (Hospital, Clinic, Research center), by method (Prenatal, Molecular, cytogenetic, presymptomatic), by application (Forensic science institute) - Global Forecast 2024

Human Genetics Market:

Genetics is the study of genes, their functions and their effects. Among the various types of genetics such as molecular genetics, developmental genetics, population genetics and quantitative genetics, human genetics is the study that deals with the inheritance occurs in human beings. It encompasses a variety of overlapping fields such as classical genetics, cytogenetic, molecular genetics, genomics and many more.

The study of human heredity occupies a central position in genetics. Much of this interest stems from a basic desire to know who humans are and why they are as they are. It can be useful as it can answer questions about human nature, understand the diseases and development of effective disease treatment, and understand genetics of human life. At a more practical level, an understanding of human heredity is of critical importance in the prediction, diagnosis, and treatment of diseases that have a genetic component.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/714

Key Players of Human Genetics Market:

Market Segmentation:

Major Human Genetics Market by Methods: Cytogenetic, Molecular, Presymptomatic and Prenatal.

Human Genetics Market by Product: Consumables, Devices and Accessories.

Human Genetics Market by Applications: Research, Diagnostic and Forensic Science and Others.

Human Genetics Market by End-Users: hospitals, clinics, research centers and forensic departments.

Human Genetics Market Growth Influencer:

The growth driver includes advancement of genetics testing technologies, rising genetic diseases, and rising awareness in terms of increasing knowledge about the potential benefits in genetic testing. Furthermore, aging population and increasing incidence of cancer cases are the other factors propelling growth of human genetics market.

The market for screening the newborns, diagnosing rare and fatal disorders, and predicting the probability of occurrence of abnormalities & diseases are likely to expand. Particularly, genetic tests to screen the newborns are expected to expand immensely over the coming years. Furthermore, the genetic disorders caused by microorganisms such Zika virus is one of the major concern behind of microcephaly. Microcephaly is a birth defect that is associated with a small head and incomplete brain development in newborns that transferred from mother to her child. Such, diseases are expected raise the application of the human genetic studies there by driving by the market. However, the high costing instruments and lack of experienced professionals are the major restraints for the growth of Human genetics market.

Access Report Details @ https://www.marketresearchfuture.com/reports/human-genetics-market

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Media Contact Company Name: Market Research Future Contact Person: Akash Anand Email: akash.anand@marketresearchfuture.com Phone: +1 646 845 9312 Address:Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India City: Pune State: Maharashtra Country: India Website: https://www.marketresearchfuture.com/reports/human-genetics-market

Excerpt from:
Human Genetics Market Analysis and Global Forecast to 2024 ... - Digital Journal

Posted in Human Genetics | Comments Off on Human Genetics Market Analysis and Global Forecast to 2024 … – Digital Journal

How the genomics revolution could finally help Africa : Nature News … – Nature.com

Posted: at 4:23 pm

Nana Kofi Acquah

The genomes of Africans and people of recent African descent house a huge amount of diversity that scientists have only begun to explore.

It took a public-health disaster for the Zimbabwean government to recognize the power of precision medicine. In 2015, the country switched from a standard three-drug cocktail for HIV to a single-pill combination therapy that was cheaper and easier for people to take every day. The new drug followed a World Health Organization recommendation to incorporate the antiretroviral drug efavirenz as a first-line therapy for public-health programmes. But as tens of thousands of Zimbabweans were put onto the drug, reports soon followed about people quitting it in droves.

Collen Masimirembwa, a geneticist and founding director of the African Institute of Biomedical Science and Technology in Harare, was not surprised. In 2007, he had shown that a gene variant carried by many Zimbabweans slows their ability to break down efavirenz1. For those with two copies of the variant about 20% of the population the drug accumulates in the bloodstream, leading to hallucinations, depression and suicidal tendencies. He had tried to communicate this to his government, but at the time efavirenz was not a staple of the country's HIV programme, and so the health ministry ignored his warnings.

Masimirembwa continued to publish his research, but the authorities took no heed until there was trouble. A lot of confusion could have been avoided if the government had listened, he says, It's not a bad drug. We just know it can be improved in Africa.

Masimirembwa is a rare breed. Although scientists worldwide have been pushing for ways to improve health care by tailoring diagnostics and treatment to the environment, lifestyle and genes of individual patients, few researchers have taken this precision-medicine approach in Africa.

That may be changing. In the past five years, international research-funding organizations have invested more than US$100 million in projects to boost genetic research on people in Africa. These studies could lead to improved treatments for Africans as well as for people of recent African descent in Europe and the Americas, who tend to experience more ill health than other ethnicities a situation that is often attributed to socioeconomic challenges, but which some scientists say could also have genetic roots.

Although few would question the importance of African genomics, opinions differ on whether this will translate into better care. Globally, precision medicine has failed to live up to its promise, even in countries that spend lots of money on health. And some argue that the money spent on investigating genes should instead be used to improve basic health care on the continent.

Many African scientists bristle at that simple calculus. They are frustrated that they have been left out of research on everything from health to human origins a field that has particularly benefited from African genome data and they want Africans to gain from the work. For Masimirembwa and others, the money presents an opportunity to take control of how genetic data are collected and used. Unless capacity is built on the continent, Africans won't have a chance to participate, he says.

There's a big problem, however. Precision medicine is expensive. For a continent that, for the most part, struggles to provide even basic health care, tailor-made treatments for individual patients may seem like an unaffordable luxury.

Enter 'precision public health' a new approach to precision medicine that bases health decisions on populations and communities rather than on individuals. It would use genomic insights into a country's population to inform general treatment programmes. For instance, a country might tweak its essential medicines list that specifies the drugs it buys in bulk at reduced rates from pharmaceutical companies, to avoid medicines that are known to cause problems in its population.

This is already happening in some places. Botswana a middle-income country stopped using the three-in-one drug containing efavirenz in 2016, opting instead for a newer and better-performing, but more expensive, drug called dolutegravir. The gene variant that causes problems with efavirenz is common in Botswana around 13.5% of the population has two copies of it. And in 2015, Ethiopia banned the use of the painkiller codeine, because a high proportion of people in the country carry a gene variant that causes them to rapidly convert the drug into morphine, which can cause breathing problems or even death.

Nana Kofi Acquah

Given the continents striking diversity, a one-size-fits-all approach to public health can lead to problems.

The precision public-health approach has great appeal for technology-savvy funding organizations that are eager to make a big impact on health. For instance, last October, the Bill & Melinda Gates Foundation and the Alliance for Accelerating Excellence in Science in Africa (AESA), a funding platform based in Nairobi, Kenya, held a precision public-health summit in Ethiopia's capital Addis Ababa. The European Commission is drawing up plans for a precision public-health initiative. And AESA, which is supported by global funders and African organizations, also plans to expand into precision public health.

But to fulfil this vision, a lot of research needs to be done on African genomes. Most genomic studies so far have focused on white people of European descent. A meta-analysis published in Nature last year2 revealed that only 3% of global genome-wide association studies which link genetic traits to patterns in health, disease or drug tolerance had been performed on Africans, compared with 81% on people of European ancestry.

An added challenge is that Africans are the most genetically varied people on Earth. Africa is where humanity originated and where humans have lived the longest, so populations there have diverged more than on other continents. Its people have genetic variants that are found nowhere else.

These two factors mean that scientists are missing a big piece of the puzzle when it comes to human genetics, says Charles Rotimi, founding director of the National Institutes of Health's Center for Research on Genomics and Global Health in Bethesda, Maryland. Tests developed to inform treatment options for white people might be unsuitable for Africans and people of recent African descent. We are in a position to make wrong diagnoses, he says.

Rotimi is one of the founders of the Human Heredity and Health in Africa (H3Africa) Initiative, created in 2010 by the London-based biomedical charity the Wellcome Trust and the US National Institutes of Health. Aiming to build genomics research capacity in Africa, the first round of the programme distributed $70 million to African scientists who teamed up with partners from the United States and Europe (see 'An evolving consortium'). A second round, worth around $64 million, is at the application stage.

Source: h3Africa

The research targets conundrums that have dogged clinicians for some time such as why Africans have a higher risk of developing chronic kidney disease, and do so at a younger age, than do white people. Nephrologist Dwomoa Adu at the University of Ghana Medical School in Accra, one of the principal investigators in the H3Africa Kidney Research Network, says there are no known environmental factors that explain this. But many Africans carry variants in the gene for apolipoprotein L1 (APOL1) that seem to confer an increased risk of developing kidney disease3. These variants have probably flourished in Africa because they confer resistance to trypanosomiasis, or sleeping sickness, a parasitic disease transmitted by the tsetse fly. But as life expectancy has increased in African countries, the incidence of kidney disease has risen markedly. And because there is little dialysis or kidney-transplant capacity on the continent, most people who develop the condition die, says Adu. It's a nightmare illness.

Adu's study is testing the link between the APOL1 gene and kidney disease in Africa at a greater sensitivity than previous studies. But being able to predict the disease with a gene test will be of little use in places where treatment is inaccessible. So Adu is also looking to understand the mechanism by which the gene causes disease, in the hope that this will lead to new, more-affordable, treatments. It might be possible to block the mechanism, he says.

Other H3Africa projects are looking for genetic clues to people's varying susceptibility to HIV progression, type 2 diabetes and stroke. One project is studying susceptibility to sleeping sickness. To find the genetic variations that might be causing this clinical diversity, H3Africa has created a chip for quickly assessing variation in Africans. Such chips act as a tool for genome-wide association studies by giving researchers a catalogue of variants called single nucleotide polymorphisms (SNPs) that could be linked to risk for a particular disease or drug reaction. So far, H3Africa has identified 2.7 million previously unrecorded SNPs, and many have made it onto the chip. Samples from the San a southern African indigenous group identified as the earliest genetic pool to split off from the rest of the human family tree have a particularly rich vein of new SNPs to study. We can't wait to explore them, says Nicola Mulder, a bioinformatician at the University of Cape Town in South Africa, who led work on the chip.

Although most of the H3Africa projects have yet to publish results, examples of the types of finding it might provide are starting to appear in the literature. For example, in March this year, Rotimi and his colleagues reported4 that about 1% of West Africans, African Americans and others of recent African ancestry carry a gene variant that increases their risk of obesity. And a collaboration between South African and Italian scientists resulted, also last month, in the identification of a genetic variant5 that seems to increase the carrier's risk of heart disease and cardiac arrest. The researchers identified the variant by studying a South African family that has been hit hard by the disease, whose members did not carry any gene variants previously associated with the illness. Although it is not known how common the variant is in South Africa, it could play a part in the high levels of heart disease seen in the country.

These insights could lead to better treatment for Africans and people of recent African descent, and perhaps result in discoveries about human genetics. We are all African beneath our skin, so understanding African genomes is going to be of global benefit, says Rotimi.

The attention that genomics research is getting in Africa has not been without critics. Cost is a major concern. Like most developing regions, Africa is seeing a rapid rise in non-communicable diseases such as cancer. In developed countries, cancer treatments are profoundly informed by genomics. But many African nations have only a handful of cancer specialists, and limited capacity for diagnosis and treatment. Although breast-cancer rates, for example, are lower in parts of Africa than in developed countries, more Africans die from the disease and not just because of a lack of access to care standard treatments sometimes seem less efficient in some African women. Still, basic cancer-therapy equipment may be higher on the wish list than new genomic tests tailored to African people's tumours. In April last year, for example, Uganda's only radiotherapy machine broke down, forcing people to travel to neighbouring Kenya for treatment, at their own cost.

There are those who think that projects such as H3Africa are over-stating the significance of the genetic variance between Africans and Europeans, and its effects on treatment options. Reinhard Hiller, director of the Centre for Proteomic and Genomic Research, a non-profit bioinformatics organization in Cape Town, is pleased that there is growing interest in African genomics. But he thinks that many genomic approaches, especially for treating cancer, can be applied to Africans now. A biopsy from a black woman's breast tumour can undergo the same analysis as that of a European's to look for the tell-tale genetic signs of its origin, he argues. And starting to do this, even on a small scale, might provide more informative data than focusing only on the differences, he says. We shouldn't try and prevent governments and societies in Africa from having access to cutting-edge solutions merely because they are deemed imperfect.

Insights from that could feed back to basic genomic research where outcomes warrant it. We have to be a lot more pragmatic and do whatever we can do now. If we don't get on with it we'll be sitting here in 50100 years still without answers.

His lab is one of the few in Africa that can do genomic sequencing. At the moment, most of its therapeutic work is for the private health sector in South Africa. But he's hopeful that genomic medicine can make it into the public sector. The main constraint, besides the cost, is the lack of technicians and counsellors, he says something that is also true in many wealthy countries, he adds.

But apart from the time it takes to do the research, the slow pace of government policy in Africa presents another stumbling block for the rollout of precision medicine. Masimirembwa's long-ignored advice on efavirenz in Zimbabwe is a case in point.

As it turns out, the three-in-one HIV drug that the country rolled out in 2015 works well in people who tolerate it. But differentiating those individuals from the 20% or so who will probably have a bad reaction is difficult. Masimirembwa and his colleagues developed a genetic test for the gene variant that makes carriers sensitive to the drug. This, he says, could be used to identify people who need to be given a lower dose of efavirenz something that he and his colleagues have determined decreases the risk of side effects while maintaining its efficacy. Last year he won a 500,000 rand ($39,000) commercialization grant from the South African government for his test. But he's up against the clock.

Zimbabwe's government, along with those in South Africa and Uganda, are considering going the same way as Botswana did, and ditching the efavirenz-based treatments entirely. Although the replacement drugs would not necessarily be any less effective, it would mean that Masimirembwa's test would no longer have a market a disappointing fate for his discovery.

But Masimirembwa thinks that there is still time to make good on his idea. It takes governments years to make decisions on public health, he says, and the new drugs might be unaffordable. And while the Zimbabwean government mulls over options, many HIV-positive people in the country still face a difficult choice: take the drugs that are available and experience serious side effects, or stop taking them and risk developing AIDS. There are second-line alternatives, but most patients are told to 'hang in there' to see if the side effects subside, he says. Few are offered different drugs.

One good thing has come out of the debacle so far: it has opened the government's eyes to the value of Masimirembwa's research. In February this year he was awarded a $15,000 national science award. Whilst there was initially poor acceptance of our findings, the current national and regional support is very encouraging for the future of genomic medicine, he says. And if his test makes it from the bench to the bedside, it will set a good precedent, he adds. We will have demonstrated that African scientists can take an idea from the lab to the market.

See the original post:
How the genomics revolution could finally help Africa : Nature News ... - Nature.com

Posted in Human Genetics | Comments Off on How the genomics revolution could finally help Africa : Nature News … – Nature.com

Fish study shows important genome interactions in animal cells – Science Daily

Posted: at 4:23 pm


Science Daily
Fish study shows important genome interactions in animal cells
Science Daily
All animal cells are made up of two genomes, the nuclear genome with 10,000s of protein coding genes and the mitochondrial genome with 13 protein-encoding genes. All 13 genes from the mitochondrial genome interact with approximately 76 nuclear ...

Read more here:
Fish study shows important genome interactions in animal cells - Science Daily

Posted in Genome | Comments Off on Fish study shows important genome interactions in animal cells – Science Daily

Climate change impacting ‘most’ species on Earth, even down to their genome – The Guardian

Posted: at 4:23 pm

A female kangaroo lies dead after she was hit by a car while moving to higher ground away from floodwaters in Rockhampton, Tuesday, April 4, 2017. Flood waters are expected to hit levels not seen in 60 years. Climate change is intensifying extreme weather events such as these as well as making them hit more frequently. Such events, as well as other climate impacts, are forcing animals to move around the world, often resulting in population decline and local extinction. Photograph: Dan Peled/AAP

Climate change is rapidly becoming a crisis that defies hyperbole.

For all the sound and fury of climate change denialists, self-deluding politicians and a very bewildered global public, the science behind climate change is rock solid while the impacts observed on every ecosystem on the planet are occurring faster in many parts of the world than even the most gloomy scientists predicted.

Given all this, its logical to assume life on Earth the millions of species that cohabitate our little ball of rock in space would be impacted. But it still feels unnerving to discover that this is no longer about just polar bears; its not only coral reefs and sea turtles or pikas and penguins; it about practically everything including us.

Three recent studies have illustrated just how widespread climate changes effect on life on our planet has already become.

There has been a massive under-reporting of these impacts.

It is reasonable to suggest that most species on Earth have been impacted by climate change in some way or another, said Bret Scheffers with the University of Florida. Some species are negatively impacted and some species positively impacted.

Scheffers is the lead author of a landmark Science study from last year that found that current warming (just one degree Celisus) has already left a discernible mark on 77 of 94 different ecological processes, including species genetics, seasonal responses, overall distribution, and even morphology i.e. physical traits including body size and shape.

Woodland salamanders are shrinking in the Appalachian Mountains; the long-billed, Arctic-breeding red knot is producing smaller young with less impressive bills leading to survival difficulties. Marmot and martens in the Americas are getting bigger off of longer growing seasons produce more foodstuffs, while the alpine chipmunks of Yellowstone National Park have actually seen the shape of their skulls change due to climate pressure.

Life is proving just as strange under our new climate regime when it comes to genetics. Pink salmon genetics are evolving for earlier migrations with fewer salmon encoding their genes for earlier migrations. In making its way north, the southern flying squirrel has begun hybridising with the northern flying squirrel. The water flea has seen its genetics change over just a few decades to respond to higher water temperatures.

But the fact that so many species are undergoing genetic changes doesnt mean they are successfully adapting to our warmer world.

In many instances genetic diversity is being lost due to climate change, not just in nature but also in resources that humans depend on such as crops and timber, Scheffers said. It is important to not confuse species responses and adaptation as an indicator that everything will be okay.

Scheffers and his colleagues findings are furthered by a study in Nature Climate Change this February that found that 47 percent of land mammals and 23 percent of birds have already suffered negative impacts form climate change. In all, nearly 700 species in just these two groups are flagging under climate change, according to this research.

We now have evidence that entire ecosystems, some the size of entire states within the USA, are changing.

There has been a massive under-reporting of these impacts, co-author James Watson with the University of Queensland said in a press release, pointing out that the IUCN Red List only considers seven percent of mammals and four percent of birds as threatened by climate change and severe weather. The IUCN often drags behind the latest science many species wait decades for an update while most species on Earth have never been evaluated.

In worst-case scenarios, species are simply vanishing.

A third study this one in PLOS Biology found that more than 450 plants and animals have undergone local extinctions due to climate change. Local extinction, as its name implies, doesnt mean the species are gone for good, but that they vanish from a portion of their range. For example, the barren ground shrew has seen its range constrict aggressively as its tundra home warms.

If global warming continues, species that cannot change or move quickly enough may go globally extinct, the studys author, John Wiens with the University of Arizona, said.

Such global extinctions have already happened. Last year, scientists discovered that the Bramble Cay melomys an Australian rat-like rodent went extinct recently (it was last seen in 2007) due to rising seas inundating its tiny coral island.

Its the first mammal confirmed to be pushed to extinction entirely due to climate change or one could say our fossil fuel addiction.

Wiens study also found that local extinctions were happening more in the tropics than in temperate areas. This is worrying since the tropics hold the vast bulk of the worlds biodiversity, with many tropic species still unstudied and even undiscovered by scientists.

But changes are rippling even beyond single extinctions.

We now have evidence that entire ecosystems, some the size of entire states within the USA, are changing in response to climate change, said Scheffers. He pointed to kelp forests that he said are dying and being replaced by rocky, less-productive ecosystems.

Made up of giant brown algae, kelp as tall as trees provide essential nurseries for fish, protect coastlines against worsening storm surges, store vast amounts of carbon, and provide homes for species like sea otters. But warming waters combined with ocean acidification is taking its toll.

And Scheffers expects more ecosystem shifts, as scientists describe them, in the future. Cloud forests are at risk of becoming high altitude grasslands, coral reefs of becoming algal-dominated ecosystems, and Arctic sea ice open ocean.

Given what we are seeing now, just imagine what will happen to all these species when temperatures increase by four of five times that amount, said Wiens.

If global society doesnt kick its fossil fuel addiction and quick scientists estimate that temperatures could rise 4-5 degrees Celsius by the end of the century. Such a rise would be not so much catastrophic, but apocalyptic.

One thing that is certain is that this global response to climate change points to an increasingly unpredictable future for humans, Scheffers said.

More than half of the worlds humans today live in cities but that wont make any of us immune to the changes going on in nature. According to Scheffers research, humans will see a drop in productivity of various crops or timber species, a drastic loss in marine fisheries, a potential rise in new diseases as well as disease spreading to places theyd never been before. Meanwhile, declines in coral reefs, kelp forests and mangroves could lead to more lives lost in climate-fueled storms. Loss of global biodiversity will also have knock-on effects in societies around the world, from less productive ecosystems to impacts we simply cant predict today.

I was not surprised, Scheffers said of his research. But I was alarmed. The extent of impacts is vast and has impacted every ecosystem on the Earth.

Is all this alarmist? Sure. But its high time we set off the alarms they should have started ringing in the 1980s and been deafening by the early 1990s.

Does all this imply nothing can be done? Of course not.

Governments and large organisation can invest and commit to reducing carbon emissions and protecting natural ecosystems that increase resilience to climate change not only for nature but for people as well, Scheffers said. These include large areas of connected forests which cool local and regional climate, pristine coral and oyster reefs that not only provide food but reduce storm surges, and well managed watersheds that will maintain adequate fresh water.

Wiens agreed, but added that there also needs to be more, bolder, large-scale efforts to reduce the carbon that is already in the atmosphere.

A number of companies have already produced technologies that do just that: they pull carbon out of the atmosphere. But to date, lack of money and support have delayed rolling out such devices en masse.

Meanwhile, the researchers agree that the Paris Agreement the only global agreement to tackle climate change must be protected.

Wisdom comes from combining truth with beliefs. There is a global scientific consensus around climate change and its impacts on nature and humans. It is truth that climate change will have devastating impacts on human health and quality of life, Scheffers said, noting that the Trump Administrations current flirtation with pulling out of the Paris Agreement is not only an unwise decision but a dangerous decision.

Read the original:
Climate change impacting 'most' species on Earth, even down to their genome - The Guardian

Posted in Genome | Comments Off on Climate change impacting ‘most’ species on Earth, even down to their genome – The Guardian

Fish study shows important genome interactions in animal cells – Phys.Org

Posted: at 4:23 pm

April 4, 2017 A salt water marsh, where F. heteroclitus naturally occur. Individuals used in the study were collected in marshes in Mantoloking, NJ. Inset: a male F. heteroclitus. Credit: Douglas Crawford

In a new study, researchers at the University of Miami (UM) Rosenstiel School of Marine and Atmospheric Science examined how the interaction of two genomes in animal cellsthe mitochondrial and nuclear genomesinteract to affect adaptation of the Atlantic killifish to different temperatures. They showed that although these genomes are separate physical entities, the mitochondrial genome affects the evolution of the nuclear genome, the genetic material responsible for variations in most traits such as hair color and height.

Interactions between these two genomes, which affect everything from health and physiology to fitness, have important consequences for human health and medical interventions such as mitochondrial replacement therapy in embryos.

All animal cells are made up of two genomes, the nuclear genome with 10,000s of protein coding genes and the mitochondrial genome with 13 protein-encoding genes. All 13 genes from the mitochondrial genome interact with approximately 76 nuclear genes in a single metabolic pathwaycalled the oxidative phosphorylation pathwaythat produces nearly all the metabolic energy needed for animal cells. This study found that the interaction between these genomes and the implications on energy production is strong enough that the mitochondrial genome can alter which version of a gene is present in the nuclear genome.

Using Atlantic killifish (Fundulus heteroclitus), the researchers examined whether mitochondrial-nuclear interactions alter the frequency of alternative forms of a gene that arise by mutation, called alleles, for over 11,000 nuclear DNA sequence variations within a population of the fish with mixed ancestry. Among individuals with two divergent mitochondrial haplotypes (mt-haplotypes), the genome-wide analyses revealed significant differences in nuclear allele frequencies.

"Our results suggest that metabolic fitness is not simply a function of the mitochondria but instead is reliant on mitochondrial-nuclear interactions and therefore important for our understanding of physiology, human health and evolution," said Doug Crawford, professor of marine biology and ecology at the UM Rosenstiel School.

The study, titled "Evolved genetic and phenotypic differences due to mitochondrial-nuclear interactions," was published in the March 31, 2017 issue of the journal PLoS Genetics.

Explore further: New species concept based on mitochondrial & nuclear DNA coadaptation

More information: Tara Z. Baris et al, Evolved genetic and phenotypic differences due to mitochondrial-nuclear interactions, PLOS Genetics (2017). DOI: 10.1371/journal.pgen.1006517

Journal reference: PLoS Genetics

Provided by: University of Miami

What is a species? Biologistsand ornithologists in particularhave been debating the best definition for a very long time. A new commentary published in The Auk: Ornithological Advances proposes a novel concept: that ...

Mitochondrial replacement therapy (MRT) has now been used in humans to conceive a "three-parent baby" to prevent inherited mitochondrial disorders, but there remain questions about the effectiveness of the process.

The way we age might be determined long before the aging process starts and the first signs appear. Scientists at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), in partnership with groups at the ...

(Medical Xpress) -- Researchers have discovered the first real evidence of the 'mother's curse' and its connection to male infertility due to genetic mutations in mitochondria. Led by Dr. Damian Dowling from Monash University ...

(Phys.org)Plantandanimal cells contain two genomes: one in the nucleus and one in the mitochondria. When mutations occur in each, they can become incompatible, leading to disease. To increase understanding of such ...

Diseases caused by genetic mutations in the mitochondria the powerhouses of the cell can be disabling, or even deadly. That is why mitochondrial replacement therapy (MRT), otherwise also known as three-person IVF ...

What's brightly colored, lives on shipwrecks, filter-feeds like a whale, and shoots webs like Spiderman? If you can't readily come up with an answer, that's okay: until now, such animals weren't known to science. But as of ...

When whiteflies take off, they don't just spread their wings and fly. Just .03 of an inch long, these tiny insects possess a variety of sophisticated techniques that provide them with exceptional stability in the air. Tel ...

Great apes help a person access an object when that person thinks they knowswhere it is but is mistaken, according to a study published April 5, 2017 in theopen-access journal PLOS ONE by David Buttelmann from Max Planck ...

(Phys.org)A team of researchers from several institutions in Germany has found that middle-age killifish fed the gut contents of younger killifish lived longer than normal. In their paper uploaded to the bioRxiv preprint ...

An American who fell in love with both the Great Barrier Reef and his wife via The University of Queensland has led a breakthrough discovery that could protect one of the Seven Natural Wonders. Husband-and-wife Professor ...

A detailed analysis of 39 U.S. fisheries by Duke University economists offers strong new evidence that catch shares curb the "race to fish" that compresses fishing seasons.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more here:
Fish study shows important genome interactions in animal cells - Phys.Org

Posted in Genome | Comments Off on Fish study shows important genome interactions in animal cells – Phys.Org

Screening the dark genome for disease – Medical Xpress – Medical Xpress

Posted: at 4:23 pm

April 3, 2017 by Ken Kingery Charles Gersbach, the Rooney Family Associate Professor of Biomedical Engineering at Duke University. Credit: Duke University

Researchers have developed a method to swiftly screen the non-coding DNA of the human genome for links to diseases that are driven by changes in gene regulation. The technique could revolutionize modern medicine's understanding of the genetically inherited risks of developing heart disease, diabetes, cancer, neurological disorders and others, and lead to new treatments.

The study appeared online in Nature Biotechnology on April 3, 2017.

"Identifying single mutations that cause rare, devastating diseases like muscular dystrophy has become relatively straightforward," said Charles Gersbach, the Rooney Family Associate Professor of Biomedical Engineering at Duke University. "But more common diseases that run in families often involve lots of genes as well as genetic reactions to environmental factors. It's a much more complicated story, and we've been wanting a way to better understand it. Now we've found a way."

The new technique relies on the gene-hacking system called CRISPR/Cas9. Originally discovered as a natural antiviral defense mechanism in bacteria, the system recognizes and homes in on the genetic code of previous intruders and then chops up their DNA. In the past several years, researchers have harnessed this biologic system to precisely cut and paste DNA sequences in living organisms.

In the current study, researchers added molecular machinery that can control gene activity by manipulating the web of biomolecules that determines which genes each cell activates and to what degree.

With the new tool, Gersbach and his colleagues are exploring the 98 percent of our genetic code often referred to as the "dark matter of the genome."

"Only a small fraction of our genome encodes instructions to make proteins that guide cellular activity," said Tyler Klann, the biomedical engineering graduate student who led the work in Gersbach's lab. "But more than 90 percent of the genetic variation in the human population that is associated with common disease falls outside of those genes. We set out to develop a technology to map this part of the genome and understand what it is doing."

The answer, says Klann, lies with promoters and enhancers. Promoters sit directly next to the genes they control. Enhancers, however, which modulate promoters, can be just about anywhere due to the genome's complex 3D geometry, making it difficult to discern what they're actually doing.

"If an enhancer is dialing a promoter up or down by 10 or 20 percent, that could logically explain a small genetic contribution to cardiovascular disease, for example," said Gersbach. "With this CRISPR-based system, we can more strongly turn these enhancers on and off to see exactly what effect they're having on the cell. By developing therapies that more dramatically affect these targets in the right direction, we could have a significant effect on the corresponding disease."

That's all well and good for exploring the regions of the genome that researchers have already identified as being linked to diseases, but there are potentially millions of sites in the genome with unknown functions. To dive down the dark genome rabbit hole, Gersbach turned to colleagues Greg Crawford, associate professor of pediatrics and medical genetics, and Tim Reddy, assistant professor of bioinformatics and biostatistics. All three professors work together in the Duke Center for Genomic and Computational Biology.

Crawford developed a way of determining which sections of DNA are open for business. That is, which sections are not tightly packed away, providing access for interactions with biomachinery such as RNA and proteins. These sites, the researchers reason, are the most likely to be contributing to a cell's activity in some way. Reddy has been developing computational tools for interpreting these large genomic data sets.

Over the past decade, Crawford has scanned hundreds of types of cells and tissues affected by various diseases and drugs and come up with a list of more than 2 million potentially important sites in the dark genomeclearly far too many to investigate one at a time. In the new study, Crawford, Reddy and Gersbach demonstrate a high-throughput screening method to investigate many of these potentially important genetic sequences in short order. While these initial studies screened hundreds of these sites across millions of base pairs of the genome, the researchers are now working to scale this up 100- to 1000-fold.

"Small molecules can target proteins and RNA interference targets RNA, but we needed something to go in and modulate the non-coding part of the genome," said Crawford. "Up until now, we didn't have that."

The method starts by delivering millions of CRISPR systems loaded into viruses, each targeting a different genetic point of interest, to millions of cells in a single dish. After ensuring each cell receives only one virus, the team screens them for changes in their gene expression or cellular functions.

For example, someone researching diabetes could do this with pancreatic cells and watch for changes in insulin production. Those cells that show interesting alterations are then isolated and sequenced to determine which stretch of DNA the CRISPR affected, revealing a new genetic piece of the diabetes puzzle.

The technique is already producing results, identifying previously known genetic regulatory elements while also spotting a few new ones. The results also showed it can be used to turn genes either on or off, which is superior to other tools for studying biology which only turn genes off. Different cell types also produced differentbut partially overlappingresults, highlighting the biological complexity in gene regulation and disease that can be interrogated with this technology.

"Now that we have this tool, we can go in and annotate the functions of these previously unknown but important stretches of our genome," said Gersbach. "With so many places to look, and the ability to do it quickly and robustly, we'll undoubtedly find new segments that are important for disease, which will provide new avenues for developing therapeutics."

Explore further: Controlling genes using CRISPR shows high degree of specificity

More information: CRISPRCas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome, Nature Biotechnology, nature.com/articles/doi:10.1038/nbt.3853

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:
Screening the dark genome for disease - Medical Xpress - Medical Xpress

Posted in Genome | Comments Off on Screening the dark genome for disease – Medical Xpress – Medical Xpress

Bionano Genomics Announces Immediate Availability of New Suite of Genomic Analysis Tools – Technology Networks

Posted: at 4:23 pm

Bionano Genomics has announced the immediate availability of its entirely new suite of tools for genome assembly, structural variation (SV) detection, and visualization of the genomes true structure. The Bionano Access 1.0 and Bionano Solve 3.0 software tools are released as a free download, and will be introduced during two live webinars on Wednesday, April 5.

Mark Borodkin, Bionanos Vice President, Systems Development, commented, With Bionano Access and our updated Bionano Solve analysis pipeline, we are making it easier than ever for scientists to get more value from Bionano genome maps related to their genome research. Following feedback from our customers, we have designed Bionano Access to be feature-rich, fast and intuitive. Bionano Access is also a browser-based application, allowing it to be run on an enterprise server or a lightweight laptop; Linux, Windows, macOS supported. Coupled with Bionano Solve, Bionano Access provides a powerful set of new tools for identifying structural variants or performing hybrid scaffolding, and this will benefit any scientist studying the true structure of the genome.

Bionano Access centralizes all software tools required to generate, edit, analyze and visualize Bionano maps. For Irys users, it replaces the IrysView software. It enables visualization of Bionano results in a web browser, providing instantaneous interaction with Bionano maps used for the scaffolding and SV applications.

Bionano Access also comes with a powerful variant annotation pipeline that can filter out common variants based on a database of controls, analyze trios or two samples to identify inherited and de novo SVs, and visualize and export in a dbVar-compliant VCF file for downstream analysis.

Hybrid scaffolding is enhanced with map editing, improved two-enzyme scaffolding and NCBI-compliant data exporting.

When connected with the Saphyr System it allows users to set-up experiments, start runs, monitor data quality metrics in real-time and automatically start de novo assemblies and SV discovery analysis when enough data is collected.

The Bionano Solve 3.0 assembly pipeline within Bionano Access allows users to run SV analysis or hybrid scaffolding. Bionano Solve 3.0 automatically calls SVs with unprecedented sensitivity. Insertions and deletions larger than 1 kilobasepair (kbp) are detected with more than 90% sensitivity and translocations with 98% sensitivity. Significant improvements to translocation calling and masking of common variants significantly reduces the false positive translocation calls.

The pipeline also significantly improves the hybrid scaffolding application by integrating two genome maps created separately with different nicking enzymes. Compared to the prior version, the new two-enzyme hybrid scaffolding incorporates up to 50% more NGS contigs in the assembly, improves contiguity significantly and allows for improved resolving of conflicts and correction of chimeric sequence contigs. This application continues to support any NGS data of suitable quality.

Bionano has validated these tools across a variety of patient samples, including those with undiagnosed disorders and leukemia.

We have applied Bionano genome mapping technology to a variety of cancer cell lines and primary patient leukemia samples and compared our results to those obtained by other genome mapping techniques, such as cytological karyotyping and whole genome sequencing, said James Broach, chair of Biochemistry and Molecular Biology, Pennsylvania State College of Medicine. In all cases, using the Bionano technology, we were able to detect all the translocations identified by these other techniques but were also able to detect many more translocations that had not been identified by those techniques. Moreover, we also detected hundreds of deletions and insertions that could not be seen by these other methodologies and therefore whose role in cancer onset and progression have not been evaluated. Given increased speed, lower cost, higher sensitivity and greater reliability of the Bionano technology, we surmise that it may supplant classical cytology as the primary method for clinical detection of genomic structural variation.

Bionano is introducing key new features in Bionano Access and Bionano Solve during two webinars on Wednesday April 5th, at 9 am and at 6 pm PDT / 12 pm and 9 pm EDT. They can be found online here Webinar 1: April 5th, 9am PDT and Webinar 2: April 5th, 6pm PDT and will be available shortly thereafter for replay on the Bionano website on new support pages dedicated to Bionano Access and Bionano Solve.

View original post here:
Bionano Genomics Announces Immediate Availability of New Suite of Genomic Analysis Tools - Technology Networks

Posted in Genome | Comments Off on Bionano Genomics Announces Immediate Availability of New Suite of Genomic Analysis Tools – Technology Networks

Morphing Genomes Can Harm and Help – UConn Today

Posted: at 4:23 pm

Imagine reading a blueprint thats 3.2 billion pages long.

Thats how many strands of DNA make up the human genome, the set of instructions that makes each of us who we are. Geneticists like UConn professor Rachel ONeill of the Department of Molecular & Cell Biology are deciphering that expansive blueprint to help us better understand the building blocks of life.

We now know the order and structure of between 80 to 90 percent of the human genome, ONeill said. Today, the field of genomics and the accompanying technology thats been developed has expanded to examining how DNA interacts within a single cell and how different genes are active in different tissues and even single cells across complex tissues, such as the brain.

ONeill noted that genomes can morphwhich presents the next challenges in genomic research. She focuses her research on understanding this instability: why in some cases its detrimental, such as with cancer, or how, in other cases, it provides opportunities for new species to evolve or adapt to their environment.

The focus of this effort is on the DNA in our genome that is considered selfish and recently evolved. Retroviruses are an example of that kind of DNA that our genomes all have, ONeill said. More specifically, I work on trying to understand why our genomes remain stable most of the time, while every so often a genome can fall into relative chaos or instability.

While most of us dont think about our genome every day, this type of research can have a significant impact on our lives.

It is tightly tied to our perception of ourselves in so many respects, ONeill said. For example, when we go into a doctors office and fill in the family history form, we are providing some genetic information that will guide the diagnosis and treatment of patients. Another relevance is that genomic information is a future diary in some respects as to what may happen to us as we age. Because of this, genetic information has to be handled very differently than other medical tests. For example, a cholesterol screening says something about your metabolism; but it can be altered with diet and exercise, so its not a permanent record.

ONeill oversees UConns Center for Genome Innovation, which supports faculty and student research with state-of-the-art technology, technical support, and grant project assistance. Additionally, the Center supports more than 100 labs across UConn Health and the Storrs and Avery Point campuses, so ONeill stays busy researching and mentoring students.

One of my recent memorable moments is when a student came running into my office having experienced the same discovery excitement I had as a grad student, this time on her own research, she said. She found that the retrovirus we were working on was a primary component of the chromosome we were studying. That was a gold moment!

As she continues her work on the human genome, one of her priorities as a scientist is to relate her research back to the public.

One of my goals is to promote the idea that the study of genetics is important, ONeill said. Understanding genomes can tell us so much about ourselves and our world. The study of genomics is increasingly intersecting with individuals at the most personal level, with a potential to shape the future of healthcare.

Take a tour of the Center for Genome Innovation: cgi.uconn.edu.

This article was first posted in the UConn Foundations online newsletter, Inside UConn Nation.

Continued here:
Morphing Genomes Can Harm and Help - UConn Today

Posted in Genome | Comments Off on Morphing Genomes Can Harm and Help – UConn Today

Unique genome architectures after fertilization in single-cell embryos – Science Daily

Posted: at 4:23 pm

Unique genome architectures after fertilization in single-cell embryos
Science Daily
After fertilization, maternal and paternal genomes erase some of the epigenetic memory of the previously differentiated states in order to facilitate the beginning of new life as the zygote. In the first cell cycle after fertilization the maternal ...

Visit link:
Unique genome architectures after fertilization in single-cell embryos - Science Daily

Posted in Genome | Comments Off on Unique genome architectures after fertilization in single-cell embryos – Science Daily

Eczema: Diagnosis and Treatment – WebMD

Posted: at 4:22 pm

It can be hard to tell for sure if you have eczema. Youll want to see a dermatologist or other doctor to find out.

At your appointment, your doctor will check your skin and talk with you about your symptoms, your health history in general, and any rashes or allergies that run in your family.

Based on that information, she'll decide if its eczema or something else.

Goodskincare is key. If your eczema is mild, that might be all you need, along with some changes in your daily habits.

If you have severe eczema, you may need to takemedicine for it, too.

The basics:

Soap and moisturizer. Use a mild soap or soap substitute that won't dry your skin. Youll also want a good moisturizer in cream, lotion, or ointment form. Smooth it on right after a shower or bath, as well as one other time each day.

If your eczema is severe, you may find that it helps to take baths with a small amount of bleach added to the water. That kills bacteria that live on the skin of people with eczema.

Short, warm showers. Dont take very hot or very long showers or baths. They can dry out your skin.

Stress management. Get regularexercise,and set aside time to relax. Need a few ideas? You could get together with friends, laugh, listen to music, meditate or pray, or enjoy a hobby.

Get a humidifier. Dry air can be stressful for your skin.

If your doctor decides you need meds to treat your eczema, those may include:

Hydrocortisone. Over-the-counter cream or ointment versions of it may help mild eczema. If yours is severe, you may need a prescription dose.

Antihistamines. Ones you take by mouth are available over-the-counter and may help relieve symptoms. Some of these make you drowsy, but others dont.

Corticosteroids. Your doctor may prescribe these if other treatments dont work. Always follow your doctor's directions when taking steroids by mouth.

Ultraviolet light therapy.This may help if your skin condition is severe.

Drugs that work on your immune system.Your doctor may consider these medicines -- such asazathioprine, cyclosporine, ormethotrexate -- if other treatments dont help. There are also prescription creams that treat eczema by controlling inflammation and reducing the immune system reactions. Examples include pimecrolimus (Elidel)andtacrolimus (Protopic), which you should only use for a short time if other treatments don't work -- and you should never use them on kids younger than 2, according to the FDA.

Prescription-strength moisturizers.These support the skins barrier.

SOURCE: American Academy of Dermatology.

See the original post:
Eczema: Diagnosis and Treatment - WebMD

Posted in Eczema | Comments Off on Eczema: Diagnosis and Treatment – WebMD